Blueprint Medicines (BPMC) Given a $109.00 Price Target by JMP Securities Analysts
Other analysts have also issued reports about the company. ValuEngine upgraded Blueprint Medicines from a hold rating to a buy rating in a report on Monday, April 2nd. BidaskClub lowered Blueprint Medicines from a strong-buy rating to a buy rating in a report on Thursday, March 29th. Zacks Investment Research upgraded Blueprint Medicines from a hold rating to a buy rating and set a $87.00 price target on the stock in a report on Monday, January 8th. Finally, Cowen reiterated a buy rating on shares of Blueprint Medicines in a report on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the stock. Blueprint Medicines currently has an average rating of Buy and an average price target of $87.80.
Shares of Blueprint Medicines stock opened at $86.46 on Monday. Blueprint Medicines has a one year low of $34.38 and a one year high of $109.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.98 and a quick ratio of 15.98.
In related news, Director Daniel Lynch sold 17,500 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $74.84, for a total transaction of $1,309,700.00. Following the sale, the director now owns 202,812 shares in the company, valued at $15,178,450.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director George Demetri sold 5,492 shares of the company’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $100.09, for a total value of $549,694.28. Following the sale, the director now owns 10,231 shares in the company, valued at approximately $1,024,020.79. The disclosure for this sale can be found here. Insiders have sold 89,567 shares of company stock worth $7,651,106 in the last quarter. 3.40% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Blueprint Medicines by 57.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 680 shares in the last quarter. QS Investors LLC bought a new stake in Blueprint Medicines in the fourth quarter valued at approximately $173,000. First Mercantile Trust Co. bought a new stake in Blueprint Medicines in the fourth quarter valued at approximately $183,000. Tower Research Capital LLC TRC raised its stake in Blueprint Medicines by 942.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 2,272 shares during the period. Finally, Public Employees Retirement Association of Colorado bought a new stake in Blueprint Medicines in the fourth quarter valued at approximately $227,000. Institutional investors and hedge funds own 97.75% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2018/04/17/blueprint-medicines-bpmc-given-a-109-00-price-target-by-jmp-securities-analysts.html.
About Blueprint Medicines
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.